| Dapagliflozin and cardiovascular outcomes in type 2 diabetes SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... New England Journal of Medicine 380 (4), 347-357, 2019 | 5727 | 2019 |
| SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome … TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ... The Lancet 393 (10166), 31-39, 2019 | 2601 | 2019 |
| A randomized, controlled trial of 3.0 mg of liraglutide in weight management X Pi-Sunyer, A Astrup, K Fujioka, F Greenway, A Halpern, M Krempf, ... New England Journal of Medicine 373 (1), 11-22, 2015 | 2098 | 2015 |
| The relation of depression and anxiety to life‐stress and achievement in students B Andrews, JM Wilding British journal of psychology 95 (4), 509-521, 2004 | 1558 | 2004 |
| Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation GA Bray, KK Kim, JPH Wilding, World Obesity Federation Obesity reviews 18 (7), 715-723, 2017 | 1313 | 2017 |
| Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome SR Coughlin, L Mawdsley, JA Mugarza, PMA Calverley, JPH Wilding European heart journal 25 (9), 735-741, 2004 | 1184 | 2004 |
| Management of obesity GA Bray, G Frühbeck, DH Ryan, JPH Wilding The Lancet 387 (10031), 1947-1956, 2016 | 1104 | 2016 |
| Differentiation of diabetes by pathophysiology, natural history, and prognosis JS Skyler, GL Bakris, E Bonifacio, T Darsow, RH Eckel, L Groop, ... Diabetes 66 (2), 241-255, 2017 | 1008 | 2017 |
| Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on … J Bolinder, Ö Ljunggren, J Kullberg, L Johansson, J Wilding, ... The Journal of Clinical Endocrinology & Metabolism 97 (3), 1020-1031, 2012 | 956 | 2012 |
| Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative … M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ... Circulation 136 (3), 249-259, 2017 | 730 | 2017 |
| 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial CW Le Roux, A Astrup, K Fujioka, F Greenway, DCW Lau, L Van Gaal, ... The Lancet 389 (10077), 1399-1409, 2017 | 711 | 2017 |
| Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal … TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich, RHM Furtado, ... Circulation 139 (17), 2022-2031, 2019 | 685 | 2019 |
| Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial O Mosenzon, SD Wiviott, A Cahn, A Rozenberg, I Yanuv, EL Goodrich, ... The lancet Diabetes & endocrinology 7 (8), 606-617, 2019 | 663 | 2019 |
| Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus ET Kato, MG Silverman, O Mosenzon, TA Zelniker, A Cahn, RHM Furtado, ... Circulation 139 (22), 2528-2536, 2019 | 614 | 2019 |
| Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled … PM O'Neil, AL Birkenfeld, B McGowan, O Mosenzon, SD Pedersen, ... The Lancet 392 (10148), 637-649, 2018 | 599 | 2018 |
| Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial JPH Wilding, V Woo, NG Soler, A Pahor, J Sugg, K Rohwedder, S Parikh, ... Annals of internal medicine 156 (6), 405-415, 2012 | 596 | 2012 |
| Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin J Bolinder, Ö Ljunggren, L Johansson, J Wilding, AM Langkilde, ... Diabetes, Obesity and Metabolism 16 (2), 159-169, 2014 | 574 | 2014 |
| Anti-obesity drugs: past, present and future RJ Rodgers, MH Tschöp, JPH Wilding Disease models & mechanisms 5 (5), 621-626, 2012 | 525 | 2012 |
| Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults SB Heymsfield, KR Segal, J Hauptman, CP Lucas, MN Boldrin, ... Archives of Internal Medicine 160 (9), 1321-1326, 2000 | 506 | 2000 |
| A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment JPH Wilding, P Norwood, C T'joen, A Bastien, JF List, FT Fiedorek Diabetes care 32 (9), 1656-1662, 2009 | 496 | 2009 |
